You just read:

New Head-to-Head Phase 3 Study Data Show Ponesimod Superiority Versus Aubagio® (teriflunomide) 14 mg in Adults with Relapsing Multiple Sclerosis (MS)

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

Sep 11, 2019, 10:00 ET